Возможности монотерапии моксифлоксацином внебольничной пневмонии, осложненной сепсисом
Возможности монотерапии моксифлоксацином внебольничной пневмонии, осложненной сепсисом
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М., 2006.
2. Dillindger RP, Carlet J, Masur H et al. Surviving Sepsis Campaign guidelines for of severe sepsis and septic shock. Crit Care Medecine 2004; 32: 858–73.
3. Сепсис в начале XXI века. Классификация, клинико-диагностическая концепция и лечение. Патолого-анатомическая диагностика: Практическое руководство. М.: Изд-во НЦССХ им. А.Н.Бакулева РАМН, 2004.
4. Mandell L, Bartlett J, Dowell S et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocomplement adulns. Clin Inf Dis 2003; 37: 1405–33.
5. Niederman M, Mandell L, Anzueto A et al. Guidelines for the management of adults of community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therahy and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
6. British Thoracic Society Standards Committee. BTS guidelines for the management of community-acqured pneumonia in adults.
7. Macrolides as biologic response modifiers – immunomodulatory and anti-inflammatory effects. Chest 2004; 125 (Suppl.): 415–785.
8. Martinez R, Horcajada JP, Almela M et al. Addition of a macrolides to a – lactams based empirical antibiotic regimen is associated with lower in hospita mortality for patients with bacteremic pneumococcal pneumonia. Clin Inf Dis 2003; 36: 389–95.
9. Baddour LM, Yu V, Klugman K et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–7.
10. Fogarty C, Siami G, Kochler R et al. Multicenter, openlabel, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxon sodium and erythromycin and amoxicillin-clavulanate in the treatment of serious community-acqured pneumonia in adults. Clin Inf Dis 2004; 38: 16–23.
11. Lode H, Choudhri S, Haverstock D et al. Effcacy and safety of sequential IV/PO moxifloxacin for treatment of severe community-acquired pneumonia. Critical care 2002; 6 (Suppl.): 88.
12. Glynn P, Coacley R, Killgallen I et al. Ciculating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax 1999; 54: 51–5.
2. Dillindger RP, Carlet J, Masur H et al. Surviving Sepsis Campaign guidelines for of severe sepsis and septic shock. Crit Care Medecine 2004; 32: 858–73.
3. Сепсис в начале XXI века. Классификация, клинико-диагностическая концепция и лечение. Патолого-анатомическая диагностика: Практическое руководство. М.: Изд-во НЦССХ им. А.Н.Бакулева РАМН, 2004.
4. Mandell L, Bartlett J, Dowell S et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocomplement adulns. Clin Inf Dis 2003; 37: 1405–33.
5. Niederman M, Mandell L, Anzueto A et al. Guidelines for the management of adults of community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therahy and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
6. British Thoracic Society Standards Committee. BTS guidelines for the management of community-acqured pneumonia in adults.
7. Macrolides as biologic response modifiers – immunomodulatory and anti-inflammatory effects. Chest 2004; 125 (Suppl.): 415–785.
8. Martinez R, Horcajada JP, Almela M et al. Addition of a macrolides to a – lactams based empirical antibiotic regimen is associated with lower in hospita mortality for patients with bacteremic pneumococcal pneumonia. Clin Inf Dis 2003; 36: 389–95.
9. Baddour LM, Yu V, Klugman K et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–7.
10. Fogarty C, Siami G, Kochler R et al. Multicenter, openlabel, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxon sodium and erythromycin and amoxicillin-clavulanate in the treatment of serious community-acqured pneumonia in adults. Clin Inf Dis 2004; 38: 16–23.
11. Lode H, Choudhri S, Haverstock D et al. Effcacy and safety of sequential IV/PO moxifloxacin for treatment of severe community-acquired pneumonia. Critical care 2002; 6 (Suppl.): 88.
12. Glynn P, Coacley R, Killgallen I et al. Ciculating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax 1999; 54: 51–5.
Авторы
И.Ю.Носков, В.А.Руднов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.